SUPN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Supernus Pharmaceuticals Inc (SUPN) does not present a strong buy opportunity for a beginner, long-term investor at this time. While there are some positive catalysts such as hedge fund buying and a recent price target increase by analysts, the financial performance shows a significant decline in net income and EPS. Additionally, insider selling has surged, and there are no strong trading signals or recent congress trading data to support an immediate buy decision. The current technical indicators are neutral, and the options data reflects bearish sentiment with a high Open Interest Put-Call Ratio. Given the investor's impatience and unwillingness to wait for optimal entry points, it is better to hold off on investing in SUPN for now.
The MACD is slightly positive and expanding, suggesting mild bullish momentum. RSI is neutral at 50.535, and moving averages are converging, indicating no clear trend. Key support is at 48.785, and resistance is at 51.811. The technical indicators do not strongly favor a buy at this moment.
Hedge funds are increasing their positions, with a 146.58% rise in buying over the last quarter. Analysts have raised the price target to $65, citing resolution of supply constraints for Onapgo.
Insider selling has surged by 2510.70% in the last month, indicating potential lack of confidence from company insiders. Financial performance shows a sharp decline in net income (-126.78% YoY) and EPS (-125.93% YoY). Options data reflects bearish sentiment with a high Open Interest Put-Call Ratio of 3.19.
In Q4 2025, revenue increased by 21.48% YoY to $211.57M, but net income dropped significantly to -$4.11M (-126.78% YoY). EPS also declined to -0.07 (-125.93% YoY), and gross margin slightly decreased to 78.43% (-1.53% YoY).
TD Cowen raised the price target from $60 to $65 and maintained a Buy rating, citing resolution of supply constraints for Onapgo and increased production capacity.
